DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for central nervous system disease — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCentral nervous system disease maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for central nervous system disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
endoglin (ENG) — ENG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5I04 · 2.42 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
Drug repurposing is described as studying clinically approved drugs in one disease to see if they have therapeutic value in other diseases, and this approach is considered especially important for neurological diseases because the structural complexity of the nervous system and the blood–brain barrier make traditional drug development more difficult than for diseases in other organs. A 2020 chapter discusses repurposing candidates currently in clinical trials for neurological diseases, along with potential mechanisms and preliminary results, but also outlines limitations and challenges for future investigations. No specific drugs, response rates, survival figures, or trial outcomes are reported in that abstract.
A 2016 article states there is a tremendous need for novel treatments of central nervous system diseases and that for chronic neurodegenerative disorders, no drugs are available that modify the course of these diseases. A 1999 book review notes that a textbook on outcomes in neurological and neurosurgical disorders begins with three chapters on outcomes analysis that serve to indicate the paucity of data presently available and how much remains to be done to determine the effectiveness of neurological care. A 2025 symposium summary reports that basic and clinical neuroscientists discussed cell and gene therapies, pharmaceutical innovations, and neurotechnology, and that the meeting gave reasons to be optimistic for the future of treating neurological conditions, but provides no concrete results.
A 1990 review describes that different disease processes selectively affect specific populations of neurons and that new cellular and molecular approaches have begun to clarify mechanisms of selective cell injury, but it does not report any treatment outcomes. A 2019 chapter lists 15 nervous system diseases, mostly caused by single-gene mutations, including Alzheimer’s, Parkinson’s, Huntington’s, epilepsy, and spinal muscular atrophy, but provides no data on repurposed drugs or their effects in these conditions. What is still missing across these abstracts is any controlled trial data for repurposed drugs in central nervous system diseases, any patient stratification strategy, and the funding needed to move from general optimism to specific, measurable outcomes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
IntechOpen eBooks · 2020 · 6 citations · open access
Drug Repurposing in Neurological Diseases: Opportunities and Challenges
AbstractDrug repurposing or repositioning refers to “studying of clinically approved drugs in one disease to see if they have therapeutic value and do not trigger side effects in other diseases.” Nowadays, it is a vital drug discovery approach to explore new therapeutic benefits of existing drugs or drug candidates in various human diseases including neurological disorders. This approach overcomes the shortage faced during traditional drug development in grounds of financial support and timeline. It is especially hopeful in some refractory diseases including neurological diseases. The feature that structure complexity of the nervous system and influence of blood–brain barrier permeability often becomes more difficult to develop new drugs in neuropathological conditions than diseases in other organs; therefore, drug repurposing is particularly of utmost importance. In this chapter, we discuss the role of drug repurposing in neurological diseases and make a summarization of repurposing candidates currently in clinical trials for neurological diseases and potential mechanisms as well as preliminary results. Subsequently we also outline drug repurposing approaches and limitations and challenges in the future investigations.
Neuronal Disorders: Studies of Animal Models and Human Diseases
AbstractThe peripheral nervous system and the central nervous system (CNS) are comprised of assemblies of neurons that communicate via electrical and chemical signals. Different disease processes selectively affect specific populations of neurons and/or specific cell functions (i.e., "selective vulnerability" of neurons is a principal determinant of phenotypes of disease). New cellular and molecular biological approaches have begun to clarify some of the mechanisms of selective cell injury in human diseases and their animal models. Following a brief review of the normal biology of nerve cells, we use illustrations drawn from studies of experimental and human diseases to discuss the mechanisms of structural/chemical abnormalities that occur in a variety of neuronal disorders.
Outcomes in Neurological and Neurosurgical Disorders
AbstractOutcomes in Neurological and Neurosurgical Disorders. Michael Swash (Editor). Cambridge, Cambridge University Press, 1998. Pages: 612. Price: $120. ISBN: 0-521-44327. In the preface of the text, Swash expresses the desire that this book serve as a reference for physicians, surgeons, attorneys, insurers, and others in determining the expected outcomes of numerous neurological and neurosurgical disorders. He and the distinguished authors of the 31 chapters have done an excellent job in producing a short textbook on the presently accepted treatments of nervous system pathological abnormalities, but, in my opinion, it is not a textbook on outcomes analysis in neurology and neurosurgery. The book starts out well, with three concise introductory chapters on outcomes analysis. These chapters serve to indicate the paucity of data presently available and how much remains to be done to determine the effectiveness of neurological and neurosurgical care. The fourth chapter in the Introduction section of the text...
JBS Special Issue: Innovative Screening Methodologies to Identify New Compounds for the Treatment of Central Nervous System Disorders
AbstractThere is a tremendous need for novel treatments of diseases of the central nervous system (CNS). It is widely appreciated that significant challenges are associated with first understanding the pathophysiology of chronic diseases and, second, designing new treatments. The slow progress of discovery and development can be devastating for patients, families, and caregivers as they await new treatment options. For chronic neurodegenerative disorders, drugs are not available that modify the course of these diseases.
Brain and Neuroscience Advances · 2025 · 0 citations · open access
Cambridge neuroscience symposium: Interventions and recovery
AbstractOn 10–11 September 2025, the Cambridge Neuroscience Interdisciplinary Research Centre held its eighth biennial symposium on the topic of Interventions and Recovery . The meeting saw basic and clinical neuroscientists come together from Cambridge and beyond to discuss the latest advancements in cell and gene therapies, pharmaceutical innovations and cutting-edge neurotechnology aimed at addressing neurological diseases. Here, we provide a summary of the meeting, which shined a light on reasons to be optimistic for the future of treating conditions of the nervous system.
Advances in bioinformatics and biomedical engineering book series · 2019 · 0 citations
Human Nervous System Disorders
AbstractThe nervous system (NS) is comprised of nerve cells (neurons), which transfer and process information, and neuroglia (or glial cells), which provide the supportive framework neurons need to function effectively. There are two divisions of the nervous system: central (CNS) and peripheral (PNS). The CNS consists of the brain and spinal cord and forms an intricate network of specialised cells that are responsible for coordinating all bodily functions. The PNS delivers sensory information from peripheral sensory tissues and systems to the CNS and carries motor commands from the CNS to peripheral tissues. This chapter discusses 15 diseases that directly affect the nervous system mostly caused by mutations in a single gene, with others having more complex modes of inheritance. They include Alzheimer's Disease, epilepsy, essential tremor, familial Mediterranean fever, Friedreich's ataxia, Huntington's disease, maple syrup syndrome, Menkes disease, narcolepsy, Parkinson's Disease, phenylketonuria, Refsum disease, spinal muscular atrophy, tangier disease, and spinocerebellar ataxia.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
